2024-09-22 - Analysis Report
## CVS Health Corp (CVS) Stock Analysis Report

**Company Overview:** CVS Health Corp is a healthcare company that operates pharmacy, drugstore, and health insurance businesses. 

**Performance Analysis:**

**1. Return vs. S&P 500:**
- CVS's cumulative return is **-34.31%**, significantly lower than the S&P 500 (VOO) cumulative return of **132.46%**. This indicates a significant underperformance compared to the broader market. 
- The relative divergence is **-166.77**, which falls at the 0.15 percentile compared to historical data, implying that CVS has consistently underperformed the market over the past period.

**2. Recent Price Movements:**
- Closing price: **$57.51**
- 5-day moving average: **$58.05**
- 20-day moving average: **$57.71**
- 60-day moving average: **$58.22**
- The stock is currently trading slightly below its short-term moving averages, suggesting a potential short-term downward pressure.

**3. Technical Indicators:**
- RSI: **51.25** (Neutral): The RSI indicates neither an overbought nor oversold condition, suggesting a balanced market sentiment.
- PPO: **0.17** (Weak Bullish): The PPO indicates a weak bullish signal, implying a potential for upward movement but not strong enough to confirm a sustained bullish trend.
- Delta_Previous_Relative_Divergence: **-2.74** (Short-term Downtrend): The negative value suggests a short-term downward trend in relative divergence, indicating potential bearish momentum.
- Expected Return: **14.57%**: This represents the maximum potential return over the next 5 years based on current investment levels, which can be considered a relatively optimistic projection.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2024-08-07 | 1.83 | 1.73        |
| 2024-05-01 | 1.31 | 1.7         |
| 2024-02-07 | 2.12 | 2.01        |
| 2023-11-01 | 2.21 | 2.13        |
| 2023-08-02 | 2.21 | 2.12        |

The most recent earnings report for the quarter ended August 2024 showed an EPS of 1.83, surpassing the expected EPS of 1.73. While the recent earnings beat expectations, the company continues to face headwinds from inflation and potential market volatility.

**5. Overall Analysis:**

CVS has been consistently underperforming the S&P 500, demonstrating a sustained weakness compared to the broader market. While recent earnings results have been positive, the stock's short-term technical indicators suggest potential downward pressure. The expected return, while optimistic, should be considered within the context of CVS's historical performance.

**6. Recommendations:**

Based on the analysis, CVS appears to be a risky investment with significant potential for further underperformance. While its recent earnings beat expectations, the company is still facing headwinds, and its short-term technical indicators are showing signs of weakness. Investors may want to consider holding off on investments until further evidence of a rebound in the stock price and a more convincing bullish technical outlook. 
